Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HCC antigens-specific CD8+ T lymphocytes
- Development stage
- Phase 1
- Lead developer
- Beijing YouAn Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
HCC antigens-specific CD8+ T lymphocytes is an experimental autologous adoptive cell therapy developed by Beijing YouAn Hospital for the treatment of relapsed or advanced hepatocellular carcinoma (HCC). The therapy involves isolating a patient's own CD8+ T cells and using human leukocyte antigen (HLA)-peptide multimers to select for cells specific to three key tumor-associated antigens: Glypican-3 (GPC3), Cancer/testis antigen 1 (NY-ESO-1), and alpha-fetoprotein (AFP). These selected T cells are expanded in vitro and re-infused into the patient. This approach aims to leverage the cytotoxic potential of T cells to selectively target and eliminate tumor cells expressing these antigens. In clinical trial settings, this therapy is often administered in combination with interleukin-2 (IL-2) to support T-cell persistence and Tegafur to potentially enhance the anti-tumor environment.
- Other names
- GPC3/NY-ESO-1/AFP specific cytotoxic lymphocytesSpecific HCC Antigens CD8+ T CellsHCC antigens-specific CD8+ T lymphocytes-Beijing YouAn Hospital-hepatocellular carcinoma
02
Targets
GPC3 (Glypican-3)MAGE-A1/A3–HLA-I (Melanoma-associated antigen A1/A3-derived peptide–Human leukocyte antigen class I complex)Alpha-fetoprotein-derived peptide–HLA class I complex (AFP-peptide–HLA complex)
Beyond the preview
Go deeper on HCC antigens-specific CD8+ T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCC antigens-specific CD8+ T lymphocytes.